PACB - PacBio to commence commercial shipment of Revio Systems

2023-03-07 07:43:31 ET

• PacBio ( NASDAQ: PACB ) announced the first customer shipments of Revio long-read sequencing systems, featuring significant advances in SMRT Cell design, compute, and system architecture, will commence on Mar.8, 2023.
• Together, this enables a dramatic increase in throughput and lower sequencing costs with the trusted power of HiFi chemistry, which offers exceptional accuracy and direct methylation detection.
• Revio systems will be shipped worldwide, with Mohammed Bin Rashid University of Medicine and Health Sciences set to expand their large-scale research projects with Revio.
• Additional Revio systems will also be shipped to customers in China, Japan, Korea, Netherlands, and Sweden.
• The company announced orders of 76 Revio systems in the quarter ended Dec.31, 2022 and expects to ship at least 25 Revio systems during Q1 of 2023.

For further details see: